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The primary structure of glucagon isolated from the intestine of the common dogfish, Scyliorhinus canicula, 
was established as 
5 10 15 20 25 
H S E G T F T S D Y S K Y M D N R R A K D F V Q W L M N T. 
The peptide shows four substitutions compared with human ghtcagon: Glu-3 for Gln, Met-14 for Leu, Asn- 
16 for Ser and Lys-20 for Gln. Glucagon represented the predominant molecular form of the glucagon-like 
immunoreactivity in the dogfish gut extracts demonstrating that the pathway of posttranslational processing 
of proglucagon in the gut of this fish differs markedly from the pathway in the mammalian gut. 
Edman degradation; HPLC; Radioimmunoassay; Posttranslational processing; (Elasmobranch) 
1. INTRODUCTION 
Characterization studies of islet hormones from 
the lower vertebrates have concentrated upon the 
teleostean fishes. The segregation of the endocrine 
pancreas of certain of these fishes into ‘principal 
islets’ or Brockmann bodies has greatly facilitated 
purification of the peptides and the primary struc- 
ture of glucagon has been determined for the 
anglerfish [l], catfish [2], Coho salmon [3], 
flounder [4] and daddy sculpin [S]. In the 
elasmobranchian class of fishes (sharks, rays and 
skates), however, the endocrine tissue is located, as 
in mammals, in islets distributed throughout the 
exocrine parenchyma but, unlike mammals, there 
is no topographical segregation into glucagon-rich 
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and glucagon-poor islets [a]. The primary structure 
of glucagon from an elasmobranchian fish is 
known only for one species, the electric ray 
Torpedo marmorata [7]. 
Glucagon-like immunoreactivity, measured in 
radioimmunoassays with antisera raised against 
porcine glucagon, has been detected in the in- 
testines of both teleostean and elasmobranchian 
fishes [7,8]. This material has not, however, been 
characterized and, up to the present ime, glicentin 
[9] and its COOH-terminal fragment, oxyn- 
tomodulin [lo] from the pig are the only intestinal 
glucagon-related peptides to have been isolated in 
pure form. In this investigation, the major 
molecular form of the glucagon-like immunoreac- 
tivity in the intestine of an elasmobranchian fish, 
the common dogfish (Scyliorhinus canicula), has 
been purified to homogeneity and identified as a 
29-amino acid residue peptide homologous to 
mammalian pancreatic glucagon. 
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2. MATERIALS AND METHODS 
2.1. Tissue extraction 
Intestinal tissue (317 g) from 5 adult dogfishes 
was homogenized at 4°C with 8 vols 
ethanol/O.7 M HCl (3 : 1, v/v) as previously 
described [111. After centrifugation (1600 x g, 1 h) 
and removal of ethanol from the supernatant 
under reduced pressure, an aliquot of the extract 
(2 ml) was chromatographed at 4°C on an 
analytical gel filtration column (90 x 1.6 cm) of 
Sephadex G-50 fine (Pharmacia) equilibrated with 
0.1 M ammonium acetate, pH 6.8. The column 
was eluted at a flow rate of 10 ml/h and 2.1 ml 
fractions were collected. Peptide material in the ex- 
tract was concentrated using Sep-Pak Cl8 car- 
tridges (Waters Associates) and bound material 
was eluted with acetonitrile/water/trifluoroacetic 
acid (80: 19: 1). The effluent was lyophilized. 
2.2. Purification of dogfish glucagon 
The intestinal extracts, after Sep-Pak concentra- 
tion, were redissolved in 1% (v/v) trifluoroacetic 
acid (5 ml) and chromatographed at 4°C on a 
preparative gel filtration column (100 x 2.6 cm) of 
Sephadex G-50 fine equilibrated with 1 M acetic 
acid. The column was eluted at a flow rate of 
40 ml/h and 6.6 ml fractions were collected. Frac- 
tions containing glucagon-like immunoreactivity 
were pooled, lyophilized and redissolved in 0.1% 
trifluoroacetic acid (1 ml). The sample was in- 
jected onto a semi-preparative Supelcosil 
LC-18-DB column (250 x 10 mm) maintained at 
30°C and at a flow rate of 2 ml/min. The column 
was eluted with a linear gradient (volume 120 ml) 
formed from acetonitrile/water/trifluoroacetic 
acid (21 .O : 78.9 : 0.1) and acetonitrile/water/tri- 
fluoroacetic acid (49.0: 50.9 : 0.1). Absorbance was 
monitored at 214 nm and 280 nm and 2 ml frac- 
tions were collected. The fraction with maximum 
glucagon-like immunoreactivity was lyophilized 
and redissolved in 0.1% trifluoroacetic acid (1 ml). 
The sample was injected onto a Supelcosil LC-3DP 
phenyl column (250 x 4.6 mm) maintained at 30°C 
and at a flow rate of 1.5 ml/min. The column was 
eluted with a linear gradient (15 ml) formed from 
0.1% trifluoroacetic acid and acetonitrile/water/ 
trifluoroacetic acid (17.5 : 82.4 : 0.1) followed by a 
linear gradient (60 ml) to acetonitrile/water/tri- 
fluoroacetic acid (45.5 : 54.4: 0.1). The peak of 
dogfish glucagon was purified to homogeneity on 
a Supelcosil LC-18-DB column (250 x 4.6 mm) 
maintained at 30°C and at a flow rate of 1.5 ml/ 
min. The column was eluted with a linear gradient 
(15 ml) formed from trifluoroacetic acid and 
acetonitrile/water/trifluoroacetic acid (28.0 :
71.9:O.l) followed by a linear gradient (90 ml) to 
acetonitrile/water/trifluoroacetic acid (45.5 : 
54.4 : 0.1). 
2.3. Structural analysis 
Amino acid composition was determined on 
1 nmol peptide using a Durrum D-500 automatic 
analyser. The primary structure of the peptide was 
determined by automated Edman degradation us- 
ing an Applied Biosystems model 470A gas phase 
sequencer [ 121. The detection limit for phenyl- 
thiohydantoin (PTH)-amino acids was 0.5 pmol. 
Approx. 2 nmol of peptide was used for the deter- 
mination. 
2.4. Radioimmunoassay methods 
Glucagon-like immunoreactivity in fractions of 
chromatographic effluent was measured using an 
antibody directed against a site in the 
NH*-terminal to central region of mammalian 
glucagon (probably residues 10-18) [13]. The im- 
munochemical properties of dogfish glucagon were 
also studied using Unger antiserum 30K directed 
against a site in the COOH-terminal region of 
.;lucagon (probably residues 24-29) [ 141. 
3. RESULTS 
3.1. Glucagon-like immunoreactivity in dogfish 
gut extracts 
Extracts of dogfish gut contained glucagon-like 
immunoreactivity equivalent o 31 pmol/g wet wt 
measured with an antiserum directed against the 
NHz-terminal to central region of glucagon and 
5 pmol/g measured with a COOH-terminally 
directed antiserum. These values must be taken as 
approximations, as the immunoreactivity in the ex- 
tracts, measured with either antiserum, did not 
elute exactly in parallel with the porcine glucagon 
standard curve in radioimmunoassays. As shown 
in fig.1, the glucagon-like immunoreactivity in an 
aliquot of the gut extracts was eluted from an 
analytical gel filtration column as a major peak 
with an elution volume slightly less than that of 
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Fig. 1. Elution profile on Sephadex G-50 of an extract of 
dogfish intestine. Glucagon-like immunoreactivity was 
measured (A) using an antiserum directed against the 
COOH-terminal region of glucagon (C-GLI) and (B) 
using an antiserum directed against the NHz-terminal to 
central region of glucagon (N-GLI). The arrows show 
the void volume (Vo) and the elution positions of porcine 
glicentin and glucagon. 
porcine glucagon. The component showed greater 
immunoreactivity with the NH?-terminally than 
with the COOH-terminally directed antiserum. A 
minor component of higher molecular mass was 
immunoreactive towards the NHz-terminal anti- 
serum only. 
3.2. Purification of dogfish g/wagon 
The glucagon-like immunoreactivity in the gut 
extracts, after concentration on Sep-Pak Cl8 car- 
tridges, was eluted from a preparative gel filtration 
column as a broad major peak with Kav between 
0.49 and 0.70. Fractions with maximum im- 
munoreactivity were purified further by reverse- 
phase HPLC on a semi-preparative octadecyldi- 
methylsilylsilica (C18) column (fig.2). Glucagon- 
like immunoreactivity was eluted from the column 
as a major peak with retention time between 45 
and 46 min which corresponded with a prominent 
peak of UV-absorbance (peak B in fig. 1). A second 
peak of glucagon-like immunoreactivity (peak A) 
was eluted from the column with retention time 
w 
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YI 
Lo 
a 3 
f 
x 
m 
a 
0 
Fig.2. Reverse-phase HPLC on a Supelcosil LC-18-DB 
column of dogfish glucagon after partial purification by 
gel permeation chromatography. Glucagon-like 
immunoreactivity was measured in the fractions denoted 
A and B in the ratio 1: 3. Peak B was purified further. 
(- - -) Concentration of acetonitrile in the eluting 
solvent. 
,,,’ _d 
Fig.3. Reverse-phase HPLC on a Supelcosil LC3-DP 
column of dogfish glucagon (peak B in fig. 1). The peak 
denoted by the asterisk contained glucagon-like 
immunoreactivity. (- - -) Concentration of acetonitrile 
in the eluting solvent. 
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between 38 and 39 min and constituted approx. 
30% of the immunoreactivity in peak B. Treat- 
ment of peak B material with hydrogen peroxide 
under the conditions described in [ 151 resulted in a 
change in retention time of the glucagon-like im- 
munoreactivity to approx. 38 min suggesting that 
peak A may be an oxidized form of glucagon. The 
major component (peak B) was further purified by 
Fig.4. Purification to homogeneity of dogfish glucagon 
on a Supelcosil LC-18-DB column. The peptide was 
characterized by amino acid composition and Edman 
degradation. The arrow shows the retention time of 
porcine glucagon. 
Table 1 
Amino acid composition of dogfish glucagon compared 
with human glucagon 
Residue Dogfish Human 
Asx 
Thr 
Ser 
GLX 
Gly 
Ala 
Val 
Met 
Leu 
Tyr 
Phe 
His 
LYS 
Arg 
4.65 (5) 
2.90 (3) 
3.79 (3) 
2.45 (2) 
1.29 (1) 
1.20 (1) 
1.05 (1) 
1.85 (2) 
0.96 (1) 
1.79 (2) 
1.97 (2) 
0.98 (1) 
2.17 (2) 
1.79 (2) 
4 
3 
4 
3 
1 
1 
1 
1 
2 
2 
2 
1 
1 
2 
Tryptophan was not determined and the numbers in 
parentheses represent the values from the sequence 
determination 
chromatography on a diphenylmethylsilylsilica 
column (fig.3). The prominent peak denoted by 
the asterisk displayed glucagon-like immunoreac- 
tivity. Dogfish glucagon was purified to homo- 
geneity by chromatography on an analytical 
reverse-phase Cl8 column (fig.4). The final yield 
of purified material was approx. 3 nmol. 
3.3. Structural analysis 
The amino acid composition of’ dogfish 
glucagon (table 1) indicated a peptide of 28-29 
residues that was structurally different from mam- 
malian glucagon. The strong absorbance of the 
Table 2 
Automated Edman degradation of dogfish glucagon 
Cycle no. PTH-amino acid Yield (pmol) 
1 His 165 
2 Ser 176 
3 Glu 327 
4 GUY 246 
5 Thr 104 
6 Phe 291 
7 Thr 125 
8 Ser 80 
9 Asp 100 
10 Tyr 177 
11 Ser 44 
12 LYS 101 
13 Tyr 183 
14 Met 138 
15 Asp 101 
16 Asn 159 
17 Arg 86 
18 Arg 102 
19 Ala 113 
20 LYS 66 
21 Asp 73 
22 Phe 136 
23 Val 118 
24 Gin 98 
25 Trp 58 
26 Leu 97 
27 Met 87 
28 Asn 12 
29 Thr 23 
The average repetitive yield was 95.4% 
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Table 3 
A comparison of the sequences of glucagon from the dogfish (Scyliorhinus 
canicula), human, Torpedo and Coho salmon 
5 10 15 20 25 
Dogfish HSEGTFTSDYSKYMDNRRAKDFVQWLMNT 
Human --Q--------_-L-~-__Q--_------ 
Torpedo -----------__L--___--__------ 
Salmon - - - - __sN-__--QEE-M-Q-_-----_S 
April 1987 
peptide at 280 nm suggested that an additional 
tryptophan residue was probably present in the 
molecule. Unambiguous assignation of 29 amino 
acid residues was possible by automated Edman 
degradation (table 2). Although approx. 2 nmol of 
peptide (estimated by amino acid analysis) had 
been subjected to sequence analysis, the yields of 
PTH-amino acids were much lower than expected. 
This may have been a result of irreversible binding 
of the highly purified peptide to the walls of the 
polypeptide tube used for the final lyophilization 
step or may have arisen from a low initial yield in 
cycle 1 of the sequence determination. With the ex- 
ception of a high relative amount of serine and 
glutamic acid, agreement between the amino acid 
composition data and the proposed sequence was 
good. High values for the amounts of serine and 
glutamic acid in peptides have been observed on 
previous occasions when relatively small quantities 
of material have been used for analysis and may 
represent carry-over from previous samples ap- 
plied to the ion-exchange column of the automatic 
analyser. As antiserum 30K will bind only those 
glucagon-related peptides with a free COOH group 
at position Thr-29 [16] the immunohistochemical 
properties of dogfish glucagon indicate hat the 
peptide is not extended beyond residue 29. The 
primary structure of dogfish glucagon is compared 
with glucagons from the human, T. marmorata 
(elasmobranch) and Coho salmon (teleost) in table 
3. 
4. DISCUSSION 
The primary structure of proglucagon has been 
deduced from the nucleotide sequences of angler- 
fish [17], cow [18] and hamster [19] cDNAs and 
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from DNAs prepared from human [20] and rat 
[21] genomic libraries. In the rat, preproglucagon 
mRNAs from pancreas and intestine are identical 
so that the diversity of the molecular forms of the 
proglucagon-derived gene products arises from 
different pathways of posttranslational processing 
of the primary transcript [22]. These pathways 
have recently been comprehensively reviewed 
[23,24]. In the pancreas of all species yet studied 
proglucagon is processed almost exclusively to 
glucagon but in the intestine of the rat [22] and pig 
[25] glucagon is virtually absent and its concentra- 
tion in the human bowel is very low [26]. The pre- 
sent study has demonstrated, therefore, that the 
pathway of posttranslational processing of pro- 
glucagon in the dogfish gut follows a completely 
different pathway from that in the mammalian in- 
testine. A high concentration of glucagon-like im- 
munoreactivity measured with an antiserum 
directed against he COOH-terminal region of por- 
cine glucagon has previously been found in ex- 
tracts of the intestine of the elasmobranchian fish, 
T. marmorata [7]. Similarly, it has also been 
shown that the intestine of the amphibian, Am- 
bystoma mexicanurn (axolotl), contains predomi- 
nantly a peptide of the same approximate mole- 
cular size as glucagon that cross-reacts strongly 
with COOH-terminally directed antisera [27]. 
Thus it may be speculated that the ability to 
regulate the processing of proglucagon differently 
in gut and pancreas may have arisen relatively late 
in evolution. 
The primary structure of glucagon has been 
highly conserved between species. The amino acid 
sequence of the peptide is identical in all mammals 
yet studied, with the exception of the guinea pig 
[ 131. In birds, substitutions are confined to Ser-28 
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for Asn in the chicken [28] and turkey [29] with the 
additional substitution Thr-16 for Ser in the duck 
[30]. Dogfish glucagon shows amino acid changes 
at four sites relative to human glucagon (table 3). 
Within the class elasmobranchii, the sequence of 
glucagon has been strongly conserved with only a 
single substitution Met-14 for Leu compared with 
the ray, T. marmoratu. Similarly, the amino acid 
composition of glucagon from the elasmo- 
branchian fish, spiny dogfish (Squalus ancanthias) 
resembled very closely that of the common dogfish 
(table 1) with two lysine and two methionine 
residues in the molecule [31]. Despite the 
similarities in trivial name, the line of evolution 
leading to the common dogfish (division 
Galeoidea) diverged from the line leading to the 
spiny dogfish (division Squaloidea) at least 
159-200 million years ago. In contrast, dogfish 
glucagon show eight amino acid substitutions 
when compared with glucagon from the teleostean 
fish, the Coho salmon [3]. 
The high degree of conservation of the structure 
of dogfish glucagon in the NHz-terminal to central 
region of the peptide is consistent with its strong 
reactivity towards an antiserum directed against 
this region of porcine glucagon. The reduced reac- 
tivity towards a COOH-terminally directed an- 
tiserum is, however, surprising in view of the fact 
that this region of the molecule is fully conserved. 
The presence of a lysine residue at position 20, 
however, may cause significant change in the con- 
formation adopted by the hydrophobic COOH- 
terminal antigenic site. 
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